drugset / Trial / NCT06501586
Study of SGB-3908 in Healthy Subjects and Mildly Hypertensive Subjects
Phase 1
Completed
40 enrolled
Suzhou Sanegene Bio Inc.
Innovent Biologics (Suzhou) Co. Ltd. · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetic (PK), and pharmacodynamic (PD) effects of SGB-3908 in healthy subjects and mildly hypertensive subjects. The study will be a single ascending dose (SAD) phase.
Timeline
- Start
- 2024-07-31
- Primary completion
- 2025-04-07
- Completion
- 2025-12-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | SGB-3908 | Unknown | — | Subcutaneous |